Biodexa Licenses Otsuka’s Molecular Glue for TKI-Resistant GIST
Event summary
- Biodexa has secured an exclusive global license (excluding Japan) for OPB-171775 (now MTX240), a Phase 1-ready molecular glue for GIST, from Otsuka.
- MTX240 targets TKI-resistant GIST via a novel PDE3a-SLFN12 mechanism, showing efficacy in PDX models with imatinib/sunitinib resistance.
- The deal includes upfront fees, mid-single-digit royalties, and development milestones; patents extend to 2037.
- Biodexa positions MTX240 as part of its GI/oncology pipeline, alongside Phase 3 eRapa for Familial Adenomatous Polyposis.
The big picture
Biodexa’s license of MTX240 underscores the growing interest in molecular glues as a workaround for kinase inhibitor resistance in rare cancers. The deal aligns with Biodexa’s strategy of targeting unmet needs in GI/oncology, competing in a GIST market projected to grow 6–10% annually through 2032. The orphan drug designation for GIST could accelerate regulatory pathways, but the real test will be MTX240’s ability to differentiate in a niche with limited post-TKI options.
What we're watching
- Clinical Validation
- Whether MTX240’s PDX efficacy translates to Phase 1 results in TKI-resistant GIST patients.
- Commercial Strategy
- How Biodexa prioritizes MTX240 alongside eRapa in its emerging GI/oncology focus.
- Market Dynamics
- The pace at which molecular glue technologies gain traction in rare oncology.
Related topics